Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly (5-15 mg), significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity, outperforming placebo, GLP-1 receptor agonists (semaglutide, dulaglutide), and basal insulins.
Tirzepatide is a once-weekly injection approved for type 2 diabetes and obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to lower blood sugar and reduce appetite. Clinical trials show it leads to significant weight loss (up to 22% in obesity) and better blood sugar control than many existing medications, including standard GLP-1 drugs and insulin. Treatment starts at a low dose to manage side effects like nausea, which usually decrease over time.
Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine... In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks.
Why this rating
Based on multiple phase 3 randomized controlled trials (SURPASS program) and a dedicated obesity trial (SURMOUNT-1).
Source
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha et al. · Journal of Obesity & Metabolic Syndrome · 2023
DOI 10.7570/jomes22067
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →